Matthew Ronsheim - May 20, 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role: Officer
Signature: /s/ Matthew Ronsheim
Stock symbol: INVA
Transactions as of: May 20, 2024
Transactions value $: -$4,323
Form type: 4
Date filed: 5/21/2024, 08:15 PM
Previous filing: Mar 7, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INVA	Common Stock	Tax liability	-$4.32K	-268	-0.66%	$16.13	40.5K	May 20, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.

Remarks:

Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.